筛查发现的微钙化在真空辅助活检诊断为不确定恶性潜能乳腺病变(B3病变)后的恶性升级率:单机构366例分析
单机构回顾性分析2011—2020年因可疑微钙化行真空辅助活检诊断为B3病变并接受手术切除的366例连续病例,56例(15.3%,95%CI 11.8-19.4%)升级为恶性,其中原位癌42/366(11.5%,95%CI 8.4-15.2%)、浸润癌14/366(3.8%,95%CI 2.1-6.3%)。多因素分析显示年龄较大、微钙化范围较大、混合形态、单纯AIDEP及混合型FEA+AIDEP、FEA+AIDEP+LCIS/LIN2为独立危险因素。作者认为FEA和ALH/LIN1可考虑真空辅助切除作为最终处理,而AIDEP和LCIS/LIN2应仍以手术切除为主。
要点
- B3病变整体恶性升级率15.3%(56/366),其中原位癌11.5%、浸润癌3.8%。
- AIDEP、LCIS/LIN2及含AIDEP的混合型B3病变升级率最高(24.6%—40.0%),FEA和ALH/LIN1较低(7.5%和3.7%)。
- 微钙化范围>10 mm、混合形态、散在分布及年龄≥60岁与升级风险相关。
核心结论
- 真空辅助活检诊断为B3病变的筛查微钙化中,15.3%(56/366)手术切除后升级为恶性;FEA和ALH/LIN1可考虑真空辅助切除作为最终处理,AIDEP和LCIS/LIN2升级率过高,手术切除应仍为主要治疗方式。
研究设计与样本
- 单机构回顾性研究,纳入2011—2020年因不伴其他影像学征象的可疑微钙化行真空辅助活检、诊断为B3病变并接受手术切除及最终组织学检查的连续病例366例。
诊断标准与关键数值
- 总体恶性升级率15.3%(56/366,95%CI 11.8-19.4%),其中原位癌11.5%(42/366,95%CI 8.4-15.2%)、浸润癌3.8%(14/366,95%CI 2.1-6.3%)。
- 各B3亚型升级率:AIDEP 24.6%、LCIS/LIN2 21.4%、FEA+AIDEP 25.3%、FEA+LCIS/LIN2 20.0%、FEA+AIDEP+LCIS/LIN2 40.0%、FEA 7.5%、ALH/LIN1 3.7%。
- 单因素分析与升级正相关的变量:年龄≥60岁(p=0.008)、混合形态(p=0.018)、散在分布(p=0.001)、微钙化范围>10 mm(p=0.001)、混合型B3病变(p=0.017)。
- 多因素 logistic 回归确认的危险因素:年龄较大(p=0.029)、微钙化范围较大(p=0.001)、混合形态(p=0.007);单纯B3病变中AIDEP(p=0.011);混合型B3病变中FEA+AIDEP(p=0.001)和FEA+AIDEP+LCIS/LIN2(p=0.037)。
临床应用与阅片要点
- 作者认为,基于本研究发现,FEA和ALH/LIN1可考虑真空辅助切除作为最终处理,而AIDEP和LCIS/LIN2应仍以手术切除为主要治疗方式,因其升级率过高,不宜安全推荐真空辅助切除。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: We retrospectively investigated clinical, radiological, and pathological features of B3 lesions associated with the risk of subsequent upgrade to malignancy.
METHODS: We included consecutive vacuum-assisted biopsies (VABs) performed during 2011-2020 on suspicious microcalcifications not associated with other radiological signs diagnosed as B3 lesions and followed by surgical excision (SE) with definitive histological examination. Multiple logistic regression models were fitted to identify independent predictors of malignancy.
RESULTS: Out of the 366 B3 lesions included, 56 (15.3 %, 95 % CI 11.8-19.4 %) had upgraded to malignancy at SE: of these, 42/366 (11.5 %, 95 % CI 8.4-15.2 %) and 14/366 (3.8 %, 95 % CI 2.1-6.3 %) were in situ and invasive carcinoma, respectively. At univariate analysis, variables positively associated with upgrade to malignancy were age ≥ 60 years (p = 0.008), mixed morphology (p = 0.018), scattered distribution (p = 0,001), extension of microcalcifications > 10 mm (p = 0.001), and mixed B3 lesion (p = 0.017). Among B3 subtypes, the highest rates of upgrade were observed for AIDEP, LCIS/LIN2, FEA + AIDEP, FEA + LCIS/LIN2, and FEA + AIDEP + LCIS/LIN2 (24.6 %, 21.4 %, 25.3 %, 20.0 % and 40.0 % respectively), while FEA and ALH/LIN1 had a lower rates of upgrade (7.5 % and 3.7 %, respectively). Multiple logistic regression analysis confirmed as risk factors older age (p = 0.029), larger extension (p = 0.001) and mixed morphology (p = 0.007) of microcalcifications, AIDEP (p = 0.011) among pure B3 lesions, and FEA + AIDEP (p = 0.001) and FEA + AIDEP + LCIS/LIN2 (p = 0.037) among mixed B3 lesions.
CONCLUSIONS: Based on our findings, vacuum-assisted excision is reasonable as definitive management for FEA and ALH/LIN1, while SE should remain the mainstay of treatment for AIDEP and LCIS/LIN2, whose upgrade rates are too high to safely recommend VAE.
引用
- Bianchi S, Caini S, Vezzosi V, et al. Upgrade rate to malignancy of uncertain malignant potential breast lesions (B3 lesions) diagnosed on vacuum-assisted biopsy (VAB) in screen detected microcalcifications: Analysis of 366 cases from a single institution. Eur J Radiol. 2023. PMID: 38091661. doi:10.1016/j.ejrad.2023.111258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。